Description: Impact BioMedical Inc. focused on discovery, development, and commercialization of products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas.
Home Page: www.impactbiomedinc.com
1400 Broadfield Blvd.
Houston,
TX
77084
United States
Phone:
585-325-3610
Officers
| Name | Title |
|---|---|
| Mr. Frank D. Heuszel Esq., J.D. | Chairman & CEO |
| Mr. Todd D. Macko CPA | CFO. Secretary & Treasurer |
| Mr. Mark J. Suseck | Chief Operating Officer |
Exchange: NYSE MKT
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 18.9 |
| Price-to-Book MRQ: | 0.6949 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-09-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 1 |